Roche stakes $1 billion in cancer gene research firm
January 12, 2015Research and Development, Sales and Marketing Cancer, Foundation Medicine, Genentech, Roche, genomics, jp morgan
Roche has announced a huge billion-dollar investment in the cancer genomics research firm Foundation Medicine. Timed with the beginning of …
Daiichi-Sankyo pays $39m to settle allegations
January 12, 2015Sales and Marketing Azor, Benicar, Daiichi Sankyo, Daiichi-Sankyo, Tribenzor, Welchol, kickbacks, us justice
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
FDA approvals: 1996 versus 2014
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs
As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …
Heptares Therapeutics hires former GSK heads
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atul Pande, GSK, Heptares, Roberto Solari
UK and US-based clinical-stage drug firm Heptares Therapeutics has appointed Atul Pande and Roberto Solari to its board of directors. …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Mixed results for Biogen’s MS drug
January 9, 2015Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy
An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …
Takeda trials Teva Parkinson’s drug in Japan
January 9, 2015Sales and Marketing Azilect, CHMP, Copaxone, Parkinson's, Takeda, rasagiline
Takeda has begun late stage trials for Teva’s Parkinson’s disease drug Azilect in Japan, with the hopes of bringing the …
Sanofi and Regeneron post positive alirocumab results
January 9, 2015Sales and Marketing Regeneron, Sanofi, cholesterol, heart, statin, statins
The latest trials of the potentially blockbuster new heart drug alirocumab show it lowers cholesterol in people at moderate and …
Ashfield Meetings & Events makes two appointments
January 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Meetings, ashfield, events, ian anderson, jo brook
Healthcare event management firm Ashfield Meetings & Events has appointed Jo Brook as an engagement director and Ian Anderson joins …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Sandoz earns historic first FDA biosimilar vote
January 8, 2015Sales and Marketing FDA, Humira, Novartis, Sandoz, Zarxio, filgrastim, zarzio
Sandoz has taken a huge step forward in the race to be the first company to market a biosimilar in …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
NHS searches for healthcare innovators
January 8, 2015Medical Communications, Sales and Marketing NHS, UK, innovation, programme, sir bruce keogh
NHS England and medical director Sir Bruce Keogh have launched an NHS Innovation Accelerator Programme. The initiative will invite healthcare …
Lilly appoints head of business development
January 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing darren carroll, lilly
Eli Lilly has promoted Darren Carroll to senior vice president of its corporate business development unit. Carroll has fulfilled the …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
Gilead acquires Phenex liver disease drugs
January 7, 2015Research and Development, Sales and Marketing Farnesoid X Receptor, Gilead, liver, nafld, nash, phenex
Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …
Amgen and Novartis start cancer immunotherapy push
January 7, 2015Research and Development, Sales and Marketing Amgen, Caribou Biosciences, Intellia Therapeutics, Novartis, kite pharma
Amgen and Novartis have launched new licensing agreements with biotech companies that they hope will lead to the development of …
Liberation Unlimited promotes Danielle Guildford-Sharp
January 7, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Creston, Danielle Guildford-Sharp, health unlimited, liberation unlimited
UK marketing and communications agency Liberation Unlimited has promoted Danielle Guildford-Sharp to the role of account manager. Since joining Liberation …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
